Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project Database
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F14%3A10159015" target="_blank" >RIV/00216208:11110/14:10159015 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/14:00074886 RIV/00216208:11130/14:10159015 RIV/00216208:11140/14:10159015 RIV/00216208:11120/14:43908269 and 5 more
Result on the web
<a href="http://dx.doi.org/10.3109/10428194.2013.815349" target="_blank" >http://dx.doi.org/10.3109/10428194.2013.815349</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3109/10428194.2013.815349" target="_blank" >10.3109/10428194.2013.815349</a>
Alternative languages
Result language
angličtina
Original language name
Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project Database
Original language description
Data of 235 unselected MCL patients from the Czech Lymphoma Group Database were analysed. MIPI divided all patients into subgroups of low-risk (22%), intermediate-risk (29%) and high-risk (49%) with median overall survival:105.8 vs. 54.1 vs. 24.6 months(p < 0.001). We confirmed Ki-67 index to be a powerful single prognostic factor for overall survival (64.4 vs. 20.1 months, p < 0.001) for all patients. Our results confirmed clinical relevance of MIPI and Ki-67 for risk stratification in MCL also in therituximab era.
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
<a href="/en/project/NR9453" target="_blank" >NR9453: Therapy intensification of patients with Diffuse Large B Cell Lymphomas based on early FDG-PET positivity (prospective analysis) and retrospective evaluation of the changes in lymphoma therapy and outcome in Czech Republic within last 15 years</a><br>
Continuities
Z - Vyzkumny zamer (s odkazem do CEZ)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2014
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Leukemia and Lymphoma
ISSN
1042-8194
e-ISSN
—
Volume of the periodical
55
Issue of the periodical within the volume
4
Country of publishing house
GB - UNITED KINGDOM
Number of pages
9
Pages from-to
802-810
UT code for WoS article
000333582600013
EID of the result in the Scopus database
—